Saliva as good as blood for diagnosing hepatitis E, study suggests

July 19, 2017

A saliva test developed by researchers at the Johns Hopkins Bloomberg School of Public Health nearly matches the performance of a blood test widely used to assess recent or past hepatitis E virus (HEV) infection, a new study reports.

The findings could offer an easier, less expensive alternative to gathering data for studying and eventually treating the disease, which infects an estimated 20 million people worldwide each year and kills more than 56,000.

The paper was published in the July edition of the Journal of Immunological Methods.

Hepatitis E isn't as well known as the other viruses that cause , an acute or chronic inflammation of liver tissue, explains study lead Christopher D. Heaney, PhD, associate professor in the Bloomberg School's Department of Environmental Health and Engineering. Yet periodic outbreaks occur in places like India, Pakistan, Nepal, Bangladesh, and regions of Africa, where poor sanitation and water quality problems can infect hundreds of thousands of people at a time through a fecal-oral route.

For some who contract the virus, symptoms are so mild that they're unaware they are infected and shedding the virus in their stool. This makes it hard to identify the sources of outbreaks and prevent them. It is still unclear why for others there is a more serious course of HEV infection.

Pregnant women are especially vulnerable, with up to 30 percent dying after becoming infected through a mechanism that's currently not understood by researchers. In contrast, the overall mortality rate for hepatitis E is about 1 percent.

"Tracking outbreaks and reducing HEV infection rates have been limited by difficulties in timely diagnosis," says Heaney. "An easier diagnostic method could have substantial yields in terms of research to the success of preventative interventions.

Currently, the only ways to test for both recent and past hepatitis E is through a blood test that checks for antibodies to HEV or blood or stool tests that check for HEV genetic material. Both sample types can be difficult to collect from patients in the field, and evaluating them requires resources that are often limited in low- to middle-income countries.

To address these challenges, Heaney and his colleagues developed a new hepatitis E test that uses saliva rather than blood or stool. The current gold standard for diagnosing hepatitis E is a blood test that uses a common diagnostic platform known as ELISA (enzyme-linked immunosorbent assay), which looks for antibodies to a disease with antigens typically attached to a solid surface.

The research team's new saliva test uses a different platform in which antigens are attached to fluorescent beads. These beads can circulate more easily through a liquid, potentially encountering more antibodies to a disease if they're present in saliva. Another advantage with this bead-based technology is that it allows for testing of a number of different antigen targets within the same saliva sample. So eventually one could test for multiple different infections in a single saliva sample.

To determine how their saliva test for hepatitis E compares to the more commonly used , the Hopkins researchers worked with colleagues at a clinical diagnostics center in Dhaka, Bangladesh, where patients are often referred for testing for hepatitis E and other diseases. Colleagues there recruited 141 patients who provided both blood and ; 76 were referred to the center because of symptoms of acute viral hepatitis, and 65 were referred for reasons unrelated to acute viral hepatitis.

The blood ELISA test showed that 50 patients from the symptomatic group had evidence of a past HEV infection and 17 had evidence of a recent HEV infection. It also showed that 28 from the group with no hepatitis E symptoms had past HEV infection and two showed evidence of recent HEV infection. The saliva test nearly matched these results, with two discrepant results for past infection and four for recent infection.

The saliva test also scored high as far as sensitivity and specificity, important indicators of a test's accuracy. For past infection, sensitivity and specificity for the saliva test were 98.7 percent and 98.4 percent respectively, and for recent , sensitivity and specificity were 89.5 percent and 98.3 percent respectively.

Study participants also filled out surveys that asked whether they preferred providing samples of saliva or for testing. Unsurprisingly, an overwhelming majority responded that they preferred to submit saliva.

Besides patient preference, saliva also has the benefit of potentially simplifying hepatitis E testing in the field. Blood samples have many requirements that saliva samples don't, such as personnel specially trained for collection, the need to protect samples from heat, and sanitary disposal of needles.

"A simple and accurate saliva test would address a lot of these challenges," Heaney says.

Their current hepatitis E test still involves equipment that's impractical to use in the field. Heaney and his colleagues plan to create versions of this test using more portable devices that can be used more easily to assess individuals where outbreaks happen in the field.

Thus far, are available for diseases caused by human immunodeficiency virus (HIV), hepatitis A virus, hepatitis C virus, norovirus, cytomegalovirus, Cryptosporidium parvum, and Toxoplasma gondii.

Researchers estimate it could be several years before they are able to make the test available.

Explore further: Saliva test could offer new way to check immunity

Related Stories

Saliva test could offer new way to check immunity

December 14, 2016
New research from the University of Birmingham shows that antibody levels in saliva are linked to those in blood serum, suggesting a new method for assessment of protection against bacterial infections.

New hepatitis C treatments more effective, tolerable: FDA

May 11, 2017
(HealthDay)—Hepatitis C can be cured in about three months, allowing people with the viral disease to live longer, healthier lives, the U.S. Food and Drug Administration (FDA) says.

New test IDs genotype of hepatitis C

June 20, 2013
(HealthDay)—A new test to help doctors identify the genotype of a person's hepatitis C infection has been approved by the U.S. Food and Drug Administration.

HBV reactivation seen with DAA treatment of chronic hep C

March 13, 2017
(HealthDay)—For patients with chronic hepatitis C (CHC) treated with direct-acting antivirals (DAAs), hepatitis B virus (HBV) reactivation may occur in those with current HBV infection, according to a study published online ...

Hepatitis C nearly triples in US in 5 years

May 11, 2017
The number of hepatitis C infections have nearly tripled in the United States in the last five years, particularly among people in their 20s, researchers said Thursday.

Hepatitis B and C may be linked to increased risk of Parkinson's disease

March 29, 2017
The viruses hepatitis B and C may both be associated with an increased risk of Parkinson's disease, according to a study published in the March 29, 2017, online issue of Neurology, the medical journal of the American Academy ...

Recommended for you

Discovery of potent parasite protein may lead to new therapeutic options for inflammatory bowel conditions

November 24, 2017
A single protein from a worm parasite may one day offer new therapeutic options for treating inflammatory bowel diseases like Crohn's or Ulcerative Colitis, that avoid the potentially serious side effects of current immunosuppressant ...

Druglike molecules produced by gut bacteria can affect gut, immune health

November 23, 2017
Stanford researchers found that manipulating the gut microbe Clostridium sporogenes changed levels of molecules in the bloodstreams of mice and, in turn, affected their health.

Study explores whole-body immunity

November 21, 2017
Over the next few months, millions of people will receive vaccinations in the hope of staving off the flu—and the fever, pain, and congestion that come with it.

Drug could cut transplant rejection

November 21, 2017
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs, according to new research by Queen Mary University of London ...

Atopic eczema—one size does not fit all

November 21, 2017
Researchers from the UK and Netherlands have identified five distinct subgroups of eczema, a finding that helps explain how the condition can affect people at different stages of their lives.

Breast milk found to protect against food allergy

November 20, 2017
Eating allergenic foods during pregnancy can protect your child from food allergies, especially if you breastfeed, suggests new research from Boston Children's Hospital. The study, published online today in the Journal of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.